<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02474901</url>
  </required_header>
  <id_info>
    <org_study_id>13-1752</org_study_id>
    <nct_id>NCT02474901</nct_id>
  </id_info>
  <brief_title>Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults</brief_title>
  <acronym>QLAIV</acronym>
  <official_title>Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to determine if there is a difference in shedding (primary
      objective) and in immunogenicity and safety (secondary objectives) between HIV-positive and
      HIV-negative children and young adults who are receiving the quadrivalent live-attenuated
      influenza vaccine (QLAIV).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      QLAIV is an intranasal vaccine that works by using 4 different attenuated strains of
      influenza virus that will replicate in the nose and stimulate an immune response in
      recipients that should protect them if they are infected with one of those strains of
      influenza in the future. A couple of studies have shown an increase in duration that the
      viruses remain in the nose in immunocompromised people. Those studies were done using the
      trivalent vaccine, so the investigators would like to evaluate the quadrivalent vaccine, and
      there is still a need for additional data to help understand the duration of shedding. If
      shedding is prolonged in HIV-infected children and young adults, it would be important to
      know for contacts of those individuals who are very immunocompromised. Shedding will be
      measured by looking for influenza RNA in nasopharyngeal swabs taken at baseline, 2-5 days,
      7-10 days and 14-21 days after the intranasal immunization.

      The live-attenuated influenza vaccines have been shown to have increased effectiveness in
      children and they stimulate the immune system in a different way than the inactivated
      influenza vaccines (TIV or QIV). In this study, the investigators will have the opportunity
      to compare the immunogenicity of QLAIV, measured at baseline and 14-21 days post-vaccination,
      in HIV-infected and uninfected children, adolescents and young adults. Although prior studies
      of LAIV in HIV-infected and other immunocompromised children and adults have not shown any
      increase in serious adverse events, safety will be actively monitored for the first 30-45
      days through a study-specific questionnaire administered at each clinic or phone visit and by
      asking the subjects to keep a diary of side effects. Safety will be monitored passively
      throughout the course of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2013</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Shedding for at Least One of the Influenza Strains Included in the QLAIV in the First 21 Days After Vaccine Administration Days in HIV-positive and Control Groups.</measure>
    <time_frame>21 days</time_frame>
    <description>Measure PCR positivity for any of the influenza subtypes included in QLAIV between baseline (day 0) and the last study visit at 14-21 days after vaccine. Compare number of participants with PCR positivity for any of the vaccine-strain influenza virus strains in each patient group.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Shedding for at Least One of the Influenza Strains Included in the QLAIV Vaccine at Each of the 4 Study Visits, Days 0 (Baseline), 2-5, 7-10, and 14-21 in HIV-positive and Control Groups.</measure>
    <time_frame>day 0-21 post-vaccine</time_frame>
    <description>Measure PCR positivity for any of the influenza subtypes included in QLAIV at visit 1 (day 0), visit 2 (days 2-5), visit 3 (days 7-10) and visit 4 (days 14-21). Compare number of participants with shedding for any subtype in each patient group. (The study was powered based on the 7-10 day data.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events Within 14 Days After Vaccination</measure>
    <time_frame>14 days after vaccination for AEs; up to 30 days for unscheduled visits</time_frame>
    <description>The investigators will compare the number of adverse events (AE) reported by AE category within 14 days after vaccination as reported by each participant. Data will reflect whether a participant ever reported the AE, and not the number of times the AE was reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Reaching Seroprotection (HAI ≥ 40) Within the HIV-positive and Control Groups.</measure>
    <time_frame>14-21 days</time_frame>
    <description>The investigators will measure hemagglutinin inhibition (HAI) on blood samples #2 (14-21 days after vaccination) for all participants. The investigators will also compare the number of participants reaching HAI ≥ 40 for each virus sub-type contained in the vaccine.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With PCR-diagnosed Influenza and Clinically-diagnosed Influenza Like Illness.</measure>
    <time_frame>up to 11 months post-vaccination</time_frame>
    <description>Compare numbers of participants with influenza diagnosed by PCR and with clinically-diagnosed influenza between the two groups. Data was taken from Influenza Infection Questionnaires #1 and #2. The last questionnaire (#2) was administered between May 15 and June 10, 2014 (after the vaccine). Data is reported as PCR-confirmed influenza and clinically-diagnosed influenza (subject told had influenza without confirmatory testing).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Human Immunodeficiency Virus (HIV)</condition>
  <arm_group>
    <arm_group_label>QLAIV, HIV-infected</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>QLAIV administered to HIV-infected individuals 2 to 25 yoa</description>
  </arm_group>
  <arm_group>
    <arm_group_label>QLAIV, HIV-uninfected</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>QLAIV administered to HIV-uninfected individuals 2 to 25 yoa</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent Live Attenuated Influenza Vaccine</intervention_name>
    <arm_group_label>QLAIV, HIV-infected</arm_group_label>
    <arm_group_label>QLAIV, HIV-uninfected</arm_group_label>
    <other_name>FluMist Quadrivalent</other_name>
    <other_name>QLAIV</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 2-25

          -  Only supposed to get one dose of vaccine for upcoming influenza season

          -  No viral respiratory symptoms at time of immunization

          -  HIV-infected group: must have:

               -  HIV-infection documented by 2 tests such as positive serology, positive HIV DNA
                  or positive HIV RNA;

               -  must thave a CD4&gt;25% or 500, or

               -  must have CD4&gt;15% or 200 and be on HAART

          -  Healthy controls: no major medical problems affecting the immune system

          -  Recruited among:

               -  HIV-unifected clients of the Children's Immunodeficiency Program(CHIP),

               -  Children's Hospital Colorado Child Health Clinic and Adolescent Clinics.

        Exclusion Criteria:

          -  History of:

               -  reactive airway disease,

               -  recurrent wheezing, or

               -  asthma

          -  Active wheezing at time of immunization

          -  On any antiviral agents active against influenza (amantadien/rimantadine, zanamavir,
             oseltamivir) at time of immunization or planned over 21 days of shedding collection

          -  Receipt of IVIG within 3 months prior to enrollment

          -  Plan to receive IVIG during the 4 weeks after immunization

          -  Moderate to severely immunocompromised individual living in the home

          -  Pregnant

          -  Breastfeeding

          -  Plan to start immunosupressive medications or stop HAART over the 4 weeks following
             immmunization

          -  Temperature &gt; 100F or 37.8C

          -  Rhinorrhea or cough not related to allergies at the time of immunization

          -  History of fungal sinusitis

          -  History of Guillain-Barre Syndrome

          -  Current on antibiotics

          -  Currently taking aspirin

          -  On an investigational drug at the time of immunization or planned over the 28 days of
             shedding collection

          -  On any experimental medication at time of immunization or planned over 21 days of
             shedding collection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adriana Weinberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myron Levin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Donna Curtis, MD,MPH</last_name>
    <role>Study Director</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2015</study_first_submitted>
  <study_first_submitted_qc>June 15, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 18, 2015</study_first_posted>
  <results_first_submitted>May 1, 2017</results_first_submitted>
  <results_first_submitted_qc>September 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">October 16, 2017</results_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Shedding</keyword>
  <keyword>Immunogenicity</keyword>
  <keyword>Safety</keyword>
  <keyword>HIV infected</keyword>
  <keyword>Children</keyword>
  <keyword>Young adults</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>QLAIV, HIV-uninfected</title>
          <description>QLAIV administered to HIV-uninfected individuals 2 to 25 yoa
Quadrivalent Live Attenuated Influenza Vaccine</description>
        </group>
        <group group_id="P2">
          <title>QLAIV, HIV-infected</title>
          <description>QLAIV administered to HIV-infected individuals 2 to 25 yoa
Quadrivalent Live Attenuated Influenza Vaccine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="45"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
                <participants group_id="P2" count="56"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>QLAIV, HIV-infected</title>
          <description>QLAIV administered to HIV-infected individuals 2 to 25 yoa
Quadrivalent Live Attenuated Influenza Vaccine</description>
        </group>
        <group group_id="B2">
          <title>QLAIV, HIV-uninfected</title>
          <description>QLAIV administered to HIV-uninfected individuals 2 to 25 yoa
Quadrivalent Live Attenuated Influenza Vaccine</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="45"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="101"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18" lower_limit="10" upper_limit="23"/>
                    <measurement group_id="B2" value="10" lower_limit="7" upper_limit="14"/>
                    <measurement group_id="B3" value="12" lower_limit="8" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Shedding for at Least One of the Influenza Strains Included in the QLAIV in the First 21 Days After Vaccine Administration Days in HIV-positive and Control Groups.</title>
        <description>Measure PCR positivity for any of the influenza subtypes included in QLAIV between baseline (day 0) and the last study visit at 14-21 days after vaccine. Compare number of participants with PCR positivity for any of the vaccine-strain influenza virus strains in each patient group.</description>
        <time_frame>21 days</time_frame>
        <population>HIV-infected and uninfected recipients of QLAIV; one HIV-uninfected subject was lost-to-follow-up after the first follow-up visit following vaccination.</population>
        <group_list>
          <group group_id="O1">
            <title>QLAIV, HIV-infected</title>
            <description>QLAIV administered to HIV-infected individuals 2 to 25 yoa
Quadrivalent Live Attenuated Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>QLAIV, HIV-uninfected</title>
            <description>QLAIV administered to HIV-uninfected individuals 2 to 25 yoa
Quadrivalent Live Attenuated Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Shedding for at Least One of the Influenza Strains Included in the QLAIV in the First 21 Days After Vaccine Administration Days in HIV-positive and Control Groups.</title>
          <description>Measure PCR positivity for any of the influenza subtypes included in QLAIV between baseline (day 0) and the last study visit at 14-21 days after vaccine. Compare number of participants with PCR positivity for any of the vaccine-strain influenza virus strains in each patient group.</description>
          <population>HIV-infected and uninfected recipients of QLAIV; one HIV-uninfected subject was lost-to-follow-up after the first follow-up visit following vaccination.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline analysis for virus (before vaccine)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Shed any virus anytime up to 21 days post-vaccine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Shedding for at Least One of the Influenza Strains Included in the QLAIV Vaccine at Each of the 4 Study Visits, Days 0 (Baseline), 2-5, 7-10, and 14-21 in HIV-positive and Control Groups.</title>
        <description>Measure PCR positivity for any of the influenza subtypes included in QLAIV at visit 1 (day 0), visit 2 (days 2-5), visit 3 (days 7-10) and visit 4 (days 14-21). Compare number of participants with shedding for any subtype in each patient group. (The study was powered based on the 7-10 day data.)</description>
        <time_frame>day 0-21 post-vaccine</time_frame>
        <population>Subjects with data for any of the visits</population>
        <group_list>
          <group group_id="O1">
            <title>QLAIV, HIV-infected</title>
            <description>QLAIV administered to HIV-infected individuals 2 to 25 yoa
Quadrivalent Live Attenuated Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>QLAIV, HIV-uninfected</title>
            <description>QLAIV administered to HIV-uninfected individuals 2 to 25 yoa
Quadrivalent Live Attenuated Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Shedding for at Least One of the Influenza Strains Included in the QLAIV Vaccine at Each of the 4 Study Visits, Days 0 (Baseline), 2-5, 7-10, and 14-21 in HIV-positive and Control Groups.</title>
          <description>Measure PCR positivity for any of the influenza subtypes included in QLAIV at visit 1 (day 0), visit 2 (days 2-5), visit 3 (days 7-10) and visit 4 (days 14-21). Compare number of participants with shedding for any subtype in each patient group. (The study was powered based on the 7-10 day data.)</description>
          <population>Subjects with data for any of the visits</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visit 1, day 0</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="45"/>
                    <count group_id="O2" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 2, days 2-5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="44"/>
                    <count group_id="O2" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 3, days 7-10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="42"/>
                    <count group_id="O2" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4, days 14-21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="43"/>
                    <count group_id="O2" value="53"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events Within 14 Days After Vaccination</title>
        <description>The investigators will compare the number of adverse events (AE) reported by AE category within 14 days after vaccination as reported by each participant. Data will reflect whether a participant ever reported the AE, and not the number of times the AE was reported.</description>
        <time_frame>14 days after vaccination for AEs; up to 30 days for unscheduled visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>QLAIV, HIV-infected</title>
            <description>QLAIV administered to HIV-infected individuals 2 to 25 yoa
Quadrivalent Live Attenuated Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>QLAIV, HIV-uninfected</title>
            <description>QLAIV administered to HIV-uninfected individuals 2 to 25 yoa
Quadrivalent Live Attenuated Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events Within 14 Days After Vaccination</title>
          <description>The investigators will compare the number of adverse events (AE) reported by AE category within 14 days after vaccination as reported by each participant. Data will reflect whether a participant ever reported the AE, and not the number of times the AE was reported.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
                <count group_id="O2" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Temperature &gt;100F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Runny nose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Nasal congestion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sore throat</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Headache</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Muscle aches</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decrease in energy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any other symptom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled medical visits in 30 days post vaccine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Looked for statistically-significant difference in numbers of adverse events between the two groups, used a p-value of 0.05 as the cutoff value for significance.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>Chi-squared, Corrected</method>
            <method_desc>Groups were compared with Yates-corrected chi-square test or Fisher exact test for binary or categorical variables.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Reaching Seroprotection (HAI ≥ 40) Within the HIV-positive and Control Groups.</title>
        <description>The investigators will measure hemagglutinin inhibition (HAI) on blood samples #2 (14-21 days after vaccination) for all participants. The investigators will also compare the number of participants reaching HAI ≥ 40 for each virus sub-type contained in the vaccine.</description>
        <time_frame>14-21 days</time_frame>
        <population>The total number of participants analyzed reflect the number of subjects for whom there was a blood sample from the 4th visit at day 14-21.</population>
        <group_list>
          <group group_id="O1">
            <title>QLAIV, HIV-infected</title>
            <description>QLAIV administered to HIV-infected individuals 2 to 25 yoa
Quadrivalent Live Attenuated Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>QLAIV, HIV-uninfected</title>
            <description>QLAIV administered to HIV-uninfected individuals 2 to 25 yoa
Quadrivalent Live Attenuated Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Reaching Seroprotection (HAI ≥ 40) Within the HIV-positive and Control Groups.</title>
          <description>The investigators will measure hemagglutinin inhibition (HAI) on blood samples #2 (14-21 days after vaccination) for all participants. The investigators will also compare the number of participants reaching HAI ≥ 40 for each virus sub-type contained in the vaccine.</description>
          <population>The total number of participants analyzed reflect the number of subjects for whom there was a blood sample from the 4th visit at day 14-21.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>H1N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>H3N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-Victoria</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B-Yamagata</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With PCR-diagnosed Influenza and Clinically-diagnosed Influenza Like Illness.</title>
        <description>Compare numbers of participants with influenza diagnosed by PCR and with clinically-diagnosed influenza between the two groups. Data was taken from Influenza Infection Questionnaires #1 and #2. The last questionnaire (#2) was administered between May 15 and June 10, 2014 (after the vaccine). Data is reported as PCR-confirmed influenza and clinically-diagnosed influenza (subject told had influenza without confirmatory testing).</description>
        <time_frame>up to 11 months post-vaccination</time_frame>
        <population>Number of participants analyzed reflects the number of subjects who participated in the end-of-season interview.</population>
        <group_list>
          <group group_id="O1">
            <title>QLAIV, HIV-infected</title>
            <description>QLAIV administered to HIV-infected individuals 2 to 25 yoa
Quadrivalent Live Attenuated Influenza Vaccine</description>
          </group>
          <group group_id="O2">
            <title>QLAIV, HIV-uninfected</title>
            <description>QLAIV administered to HIV-uninfected individuals 2 to 25 yoa
Quadrivalent Live Attenuated Influenza Vaccine</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With PCR-diagnosed Influenza and Clinically-diagnosed Influenza Like Illness.</title>
          <description>Compare numbers of participants with influenza diagnosed by PCR and with clinically-diagnosed influenza between the two groups. Data was taken from Influenza Infection Questionnaires #1 and #2. The last questionnaire (#2) was administered between May 15 and June 10, 2014 (after the vaccine). Data is reported as PCR-confirmed influenza and clinically-diagnosed influenza (subject told had influenza without confirmatory testing).</description>
          <population>Number of participants analyzed reflects the number of subjects who participated in the end-of-season interview.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PCR-confirmed influenza</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>clinically-diagnosed influenza</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <desc>HIV-infected and HIV-uninfected individuals</desc>
      <group_list>
        <group group_id="E1">
          <title>QLAIV, HIV-infected</title>
          <description>Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) administered to HIV-infected individuals 2 to 25 yoa</description>
        </group>
        <group group_id="E2">
          <title>QLAIV, HIV-uninfected</title>
          <description>Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) administered to HIV-uninfected individuals 2 to 25 yoa</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>bleeding</sub_title>
                <description>nose</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="45"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <description>Decreased appetite reported at any of the 3 follow-up visits after vaccine.</description>
                <counts group_id="E1" events="10" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Temperature &gt;100F</sub_title>
                <description>Temperature &gt;100F reported at any of the 3 follow-up visits after vaccine.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Muscle aches</sub_title>
                <description>Muscle aches reported at any of the 3 follow-up visits after vaccine.</description>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Decrease in energy</sub_title>
                <description>Decrease in energy reported at any of the 3 follow-up visits after vaccine.</description>
                <counts group_id="E1" events="16" subjects_affected="11" subjects_at_risk="45"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Any other symptoms</sub_title>
                <description>Any other symptoms reported at any of the 3 follow-up visits after vaccine.</description>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Headache reported at any of the 3 follow-up visits after vaccine.</description>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Runny nose</sub_title>
                <description>Runny nose reported at any of the 3 follow-up visits after vaccine.</description>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="45"/>
                <counts group_id="E2" events="28" subjects_affected="16" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <description>Nasal congestion reported at any of the 3 follow-up visits after vaccine.</description>
                <counts group_id="E1" events="21" subjects_affected="17" subjects_at_risk="45"/>
                <counts group_id="E2" events="24" subjects_affected="16" subjects_at_risk="55"/>
              </event>
              <event>
                <sub_title>Sore throat</sub_title>
                <description>Sore throat reported at any of the 3 follow-up visits after vaccine.</description>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="55"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Data on influenza diagnosis from the end-of-season questionnaire is limited by the number of subjects who were available to answer the questionnaire (17/45 in HIV-infected group, 53/55 in HIV-uninfected group).</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Adriana Weinberg, MD</name_or_title>
      <organization>University of Colorado</organization>
      <phone>3037244480</phone>
      <email>adriana.weinberg@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

